BioSpace News Archive

Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Oncology Conference on Thursday, Feb. 9, 2023.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting.

Avirmax Biopharma Inc. (ABI), Chief Executive and Scientific Officer, Shengjiang Shawn Liu will present the Avirmax BioPharma Inc (ABI)'s progress in the innovation and development of genetic medicines for glaucoma treatment at Glaucoma 360 New Horizons Forum at The Westin St. Francis in San Francisco, Feb 03, 2023.

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the start of its ARM vaccine manufacturing

Biosense Webster, Inc. announced that positive results from the company-sponsored STELLAR study were presented as a late breaker, titled “Pulmonary Vein Isolation of Paroxysmal Atrial Fibrillation with Multielectrode Radiofrequency Balloon Catheter: Results from the Global, Multicenter, STELLAR Study,” at the 28th Annual International AF Symposium.

Takeda announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the expanded use of TAKHZYRO® for prophylaxis to prevent attacks of hereditary angioedema in pediatric patients 2 to <12 years of age.

Bristol Myers Squibb (NYSE: BMY) today announced that the company will take part in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Conference on Thursday, February 9, 2023.

Oragenics, Inc. today announced that the Company has received formal notice from the NYSE American, LLC (“NYSE American”) stating that the Company has regained compliance with the NYSE American’s continued listing standards.

Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases, announces that research from a real-world study of netupitant or fosnetupitant with palonosetron (NEPA) has been published in the journal Future Oncology.

Recce Pharmaceuticals Ltd, the Company developing a new class of synthetic anti-infectives, announced that it has been issued a trademark for RECCE® by the Trade Marks Registry Intellectual Property Department in Hong Kong.